

AUSMEDTECH & ANDHEALTH CONFERENCES

AusMedtech and ANDHealth Winter Summit in Melbourne, 14 – 15 May 2019 and 16 May 2019:

Adelaide, Australia, 15 May 2019: LBT Innovations Limited (ASX: LBT) (LBT or the Company), a leader in medical technology automation using artificial intelligence is pleased to announce that Brent Barnes, CEO will be presenting at the 2019 AusMedtech and Australia's National Digital Health Initiative (ANDHealth) conferences.

The AusMedtech conference, at the Melbourne Convention Centre from 14th–15th May 2019, is an annual conference bringing together key stakeholders of the Australian and international medical devices and diagnostics sector to help prepare the industry for a transformational landscape. Mr Barnes will be an expert panellist in two forum sessions "Demystifying AI" and "Future Forum" discussing the future of artificial intelligence and its clinical applications.

On 16 May 2019, the ANDHealth Winter Summit will take place in the Melbourne offices of law firm, Allens, focusing on current global trends, opportunities and challenges in digital health, with the theme "Healthcare in the Data Age – Al, Avatars & Actionable Insights". Mr Barnes will be presenting on how artificial intelligence is changing the healthcare landscape in practice.

LBT is establishing itself as a leader in Artificial Intelligence in the Australian healthcare industry based on having developed the Automated Plate Assessment System, a world first FDA cleared platform utilising Al in microbiology and the ongoing work of its in-house Al team of software, engineering and subject matter experts. These conferences have attracted delegates from around Asia Pacific region and represent an opportunity for LBT to showcase its capabilities and potential to industry groups, potential customers and investors.

- ENDS -

About LBT Innovations

LBT Innovations (LBT) improves patient outcomes by making healthcare more efficient. Based in Adelaide, South Australia, the Company has a history of developing world leading products in microbiology automation. Its first product, MicroStreak®, was a global first in the automation of the culture plate streaking process. The Company's second product, the Automated Plate Assessment System (APAS®) is being commercialised through LBT's 50% owned joint venture company Clever Culture Systems AG (CCS) with Hettich Holding Beteiligungs- und Verwaltungs-GmbH. The APAS® instrument is based upon LBT's intelligent imaging and machine learning software and remains the only US FDA-cleared artificial intelligence technology for automated imaging, analysis and interpretation of culture plates following incubation.

CONTACTS

LBT Innovations	Investor Enquiries
Brent Barnes	David Allen / John Granger
Chief Executive Officer & Managing Director	Hawkesbury Partners
Tel: +61 8 8227 1555	Tel: +61 2 9103 9494
E: info@lbtinnovations.com	E: dallen@hawkesburypartners.com